EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754)
Phase 1
Completed
- Conditions
- Solid Tumor, Adult
- Interventions
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Invectys
- Target Recruit Count
- 6
- Registration Number
- NCT04515043
- Locations
- 🇫🇷
Saint Louis Hospital, Paris, France
DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia
Phase 2
Terminated
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- Biological: INVAC-1
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Invectys
- Target Recruit Count
- 26
- Registration Number
- NCT03265717
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
INVAC-1 Anti-Cancer hTERT DNA Immunotherapy
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- Biological: INVAC-1
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Invectys
- Target Recruit Count
- 26
- Registration Number
- NCT02301754
- Locations
- 🇫🇷
Hôpital Saint Louis, Paris, France
🇫🇷Hôpital Européen Georges Pompidou, Paris, France
© Copyright 2025. All Rights Reserved by MedPath